Bengaluru-based Anglo-French Drugs & Industries has launched a new product AFD-NP in the neuropathic pain segment. This is a combination of Nortriptyline + Pregabalin which is indicated to resolve moderate to severe Neuropathic Pain. This product has received approval from Drug Control Department.

Abhay Kanoria, Chairman & Managing Director, Anglo French Drugs & Industries said, “Neuropathic pain or neuropathy is commonly associated with diabetes. It has become a common disease in India and other parts of the world due to increasing incidence of Diabetes. Looking at the enormous number of patients suffering from moderate to severe neuropathy, we definitely felt the need of launching a product in this segment to alleviate the suffering of millions." 

AFD-NP is a combination of 2 molecules: Nortriptyline 10 mg and Pregabalin 75 mg. 

Patients of neuropathy are unable to sleep because of the tremendous pain and discomfort which they experience. Moreover, the pain is chronic, meaning that it lasts for many days. Nortriptyline has been shown to significantly reduce neuropathic pain and also help to increase the number of hours of sleep. This property makes it very useful in moderate to severe neuropathy.

Additionally, Pregabalin significantly reduces the number of days with pain compared to gabapentin. Furthermore, the combination of Nortriptyline and Pregabalin has good patient acceptance and tolerability.